Brainstorm Cell Therapeutics‘ investigational cell-based therapy, NurOwn, might be able to slow disease progression and be of “meaningful”…
Articles by Patricia Inácio, PhD
Prilenia Therapeutics has raised $43 million to support potential regulatory submissions and marketing of its lead candidate, pridopidine,…
A first patient has been enrolled in a Phase 3 clinical trial investigating FNP122, an oral formulation of edaravone being developed…
Amylyx Pharmaceuticals‘ global Phase 3 clinical trial investigating AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS) has begun…
AC Immune has extended its research collaboration with scientists at the University of Pennsylvania (UPenn) working to uncover how…
New early clinical study results support the potential of GN-K01, an investigational antibody being developed by GeNeuro, as a…
The ALS Association is reminding amyotrophic lateral sclerosis (ALS) patients and caregivers that the open enrollment period for Medicare…
Note: This story was updated Oct. 19, 2021, to note that the trial is taking place at 90 clinical…
Amgen and Neumora Therapeutics announced that they are collaborating to develop precision therapies for amyotrophic lateral sclerosis…
Simultaneous injections of mesenchymal stem cells (MSCs) into the blood and spinal canal were found to delay disease progression…